Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug resistant tuberculosis in Balochistan, Pakistan

References

• Abubakar, M., Ahmad, N., Atif, M., Ahmad, I., Wahid, A., Khan, A., & Ghafoor, A. (2022). Prognostic accuracy of time to sputum culture conversion in predicting cure in extensively drug-resistant tuberculosis patients: A multicentre retrospective observational study. BMC Infectious Diseases, 22(1), 1–12. https://doi.org/10.1186/s12879-022-07202-y
   PubMed Web of Science ®Google Scholar
• Abubakar, M., Ahmad, N., Ghafoor, A., Latif, A., Ahmad, I., Atif, M., Saleem, F., Khan, S., Khan, S., & Khan, A. H. (2021). Treatment outcomes of extensively drug-resistant tuberculosis in Pakistan: A countrywide retrospective record review. Frontiers in Pharmacology, 12, 640555. https://doi.org/10.3389/fphar.2021.640555
   PubMed Web of Science ®Google Scholar
• Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., Benedetti, A., Bisson, G. P., Boeree, M. J., Bonnet, M., Brode, S. K., Brust, J. C. M., Cai, Y., Caumes, E., Cegielski, J. P.,...., Menzies, D. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. The Lancet, 392(10150), 821–834. https://doi.org/10.1016/S0140-6736(18)31644-1
   PubMed Web of Science ®Google Scholar
• Ahmad, N., Javaid, A., Basit, A., Afridi, A., Khan, M., Ahmad, I., Sulaiman, S. A. S., Khan, A., & Khan, A. H. (2015). Management and treatment outcomes of MDR-TB: Results from a setting with high rates of drug resistance. The International Journal of Tuberculosis and Lung Disease, 19(9), 1109–1114. https://doi.org/10.5588/ijtld.15.0167
   PubMed Web of Science ®Google Scholar
• Ahmad, N., Javaid, A., Sulaiman, S. A. S., Afridi, A. K., & Khan, A. H. (2018). Occurrence, management, and risk factors for adverse drug reactions in multidrug resistant tuberculosis patients. American Journal of Therapeutics, 25(5), e533–e540. https://doi.org/10.1097/MJT.0000000000000421
   PubMed Web of Science ®Google Scholar
• Ahmad, N., Javaid, A., Syed Sulaiman, S. A., Basit, A., Afridi, A. K., Jaber, A. A. S., & Khan, A. H. (2016). Effects of multidrug resistant tuberculosis treatment on patients’ health related quality of life: results from a follow up study. PLoS One, 11(7), e0159560. https://doi.org/10.1371/journal.pone.0159560
   PubMed Web of Science ®Google Scholar
• Andries, A., Isaakidis, P., Das, M., Khan, S., Paryani, R., Desai, C., Dalal, A., Mansoor, H., Verma, R., Fernandes, D., Sotgiu, G., Migliori, G. B., & Saranchuk, P. (2013). High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. PLoS One, 8(10), e78313. https://doi.org/10.1371/journal.pone.0078313
   PubMed Web of Science ®Google Scholar
• Ategyeka, P. M., Muhoozi, M., Naturinda, R., Kageni, P., Namugenyi, C., Kasolo, A., Kisaka, S., & Kiwanuka, N. (2023). Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda. BMC Infectious Diseases, 23(1), 1–9. https://doi.org/10.1186/s12879-023-08085-3
   PubMed Web of Science ®Google Scholar
• Atif, M., Ahmad, W., Ahmad, N., Malik, I., & Sarwar, S. (2020). Treatment outcomes among multidrug-resistant TB patients in Bahawal Victoria Hospital, Bahawalpur, Pakistan: A retrospective record review. Transactions of The Royal Society of Tropical Medicine and Hygiene, 114(10), 733–741. https://doi.org/10.1093/trstmh/traa040
   PubMed Web of Science ®Google Scholar
• Atif, M., Ahmed, W., Nouman Iqbal, M., Ahmad, N., Ahmad, W., Malik, I., & Al-Worafi, Y. M. (2022). Frequency and factors associated with adverse events among multi-drug resistant tuberculosis patients in Pakistan: A retrospective study. Frontiers in Medicine, 8, 790718. https://doi.org/10.3389/fmed.2021.790718. eCollection 2021.
   Web of Science ®Google Scholar
• Atif, M., Bashir, A., Ahmad, N., Fatima, R. K., Saba, S., & Scahill, S. (2017). Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. BMC Infectious Diseases, 17(1), 1–12. https://doi.org/10.1186/s12879-017-2746-5
   PubMedGoogle Scholar
• Bannwarth, B. (2007). Drug-induced musculoskeletal disorders. Drug Safety, 30(1), 27–46. https://doi.org/10.2165/00002018-200730010-00004
   PubMed Web of Science ®Google Scholar
• Bloss, E., Kukša, L., Holtz, T., Riekstina, V., Skripčonoka, V., Kammerer, S., & Leimane, V. (2010). Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. The International Journal of Tuberculosis and Lung Disease, 14(3), 275–281.
   PubMed Web of Science ®Google Scholar
• Brust, J. C., Shah, N. S., Van Der Merwe, T. L., Bamber, S., Ning, Y., Heo, M., Moll, A. P., Loveday, M., Lalloo, U. G., Friedland, G. H., & Gandhi, N. R. (2013). Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes, 62(4), 436–440. https://doi.org/10.1097/QAI.0b013e31828175ed
   PubMed Web of Science ®Google Scholar
• Buajordet, I., Ebbesen, J., Erikssen, J., Brørs, O., & Hilberg, T. (2001). Fatal adverse drug events: The paradox of drug treatment. Journal of Internal Medicine, 250(4), 327–341. https://doi.org/10.1111/j.1365-2796.2001.00892.x
   PubMed Web of Science ®Google Scholar
• Burtscher, D., Van den Bergh, R., Toktosunov, U., Angmo, N., Samieva, N., & Rocillo Arechaga, E. P. (2016). “My favourite Day Is Sunday”: community perceptions of (drug-resistant) tuberculosis and ambulatory tuberculosis care in Kara Suu District, Osh Province, Kyrgyzstan. PLoS One, 11(3), e0152283. https://doi.org/10.1371/journal.pone.0152283
   PubMed Web of Science ®Google Scholar
• Furin, J. J., Mitnick, C. D., Shin, S. S., Bayona, J., Becerra, M. C., Singler, J. M., Alcantara, A. F., Castañieda,C., Sanchez, E., Acha, J., Farmert, P. E., & Kim, J. Y. (2001). Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease, 5(7), 648–655.
   PubMed Web of Science ®Google Scholar
• Gupta, V., Shivaprakash, G., Bhattacherjee, D., Udupa, K., Poojar, B., Sori, R., & Mishra, S. (2020). Association of health literacy and cognition levels with severity of adverse drug reactions in cancer patients: A South Asian experience. International Journal of Clinical Pharmacy, 42(4), 1168–1174. https://doi.org/10.1007/s11096-020-01062-9
   PubMed Web of Science ®Google Scholar
• Hoa, N. B., Nhung, N. V., Khanh, P. H., Hai, N. V., & Quyen, B. T. T. (2015). Adverse events in the treatment of MDR-TB patients within and outside the NTP in Pham Ngoc Thach hospital, Ho Chi Minh City, Vietnam. BMC Research Notes, 8(1), 1–6. https://doi.org/10.1186/1756-0500-8-1
   PubMedGoogle Scholar
• Isaakidis, P., Varghese, B., Mansoor, H., Cox, H. S., Ladomirska, J., Saranchuk, P., Silva, E. D., Khan, S., Paryani, R., Udwadia, Z., Migliori, G. B., Sotgiu, G., & Reid, T. (2012). Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One, 7(7), e40781. https://doi.org/10.1371/journal.pone.0040781
   PubMed Web of Science ®Google Scholar
• Jakasania, A., Shringarpure, K., Kapadia, D., Sharma, R., Mehta, K., Prajapati, A., & Kathirvel, S. (2020). “Side effects--part of the package”: A mixed methods approach to study adverse events among patients being programmatically treated for DR-TB in Gujarat, India. BMC Infectious Diseases, 20(1), 1–12. https://doi.org/10.1186/s12879-020-05660-w
   Web of Science ®Google Scholar
• Javaid, A., Ahmad, N., Afridi, A. K., Basit, A., Khan, A. H., Ahmad, I., & Atif, M. (2018). Validity of time to sputum culture conversion to predict cure in patients with multidrug-resistant tuberculosis: A retrospective single-center study. The American Journal of Tropical Medicine and Hygiene, 98(6), 1629–1636. https://doi.org/10.4269/ajtmh.17-0936
   PubMed Web of Science ®Google Scholar
• Javaid, A., Hasan, R., Zafar, A., Chaudry, M., Qayyum, S., Qadeer, E., Shaheen, Z., Agha, N., Rizvi, N., Afridi, M. Z., Chima, M. K., Khan, A. R., Ghafoor, A., Khan, S., Awan, S. R., Akhtar, S., Choudry, K., Iqbal, Z. H., Ansarie, M., & Ahmad, N. (2017). Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan. The International Journal of Tuberculosis and Lung Disease, 21(3), 303–308. https://doi.org/10.5588/ijtld.16.0444
   PubMed Web of Science ®Google Scholar
• Javaid, A., Shaheen, Z., Shafqat, M., Khan, A. H., & Ahmad, N. (2017). Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit. American Journal of Infection Control, 45(2), 190–193. https://doi.org/10.1016/j.ajic.2016.07.026
   PubMed Web of Science ®Google Scholar
• Khan, I., Ahmad, N., Khan, S., Muhammad, S., Khan, S. A., Ahmad, I., Khan, A., Gulalai., & Atif, M. (2019). Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. Journal of Infection and Public Health, 12(6), 809–815. https://doi.org/10.1016/j.jiph.2019.04.009
   PubMed Web of Science ®Google Scholar
• Kushemererwa, O., Nuwagira, E., Kiptoo, J., & Yadesa, T. M. (2023). Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda. SAGE Open Medicine, 11, 20503121231171350. https://doi.org/10.1177/20503121231171350
   Web of Science ®Google Scholar
• Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., Brust, J. C. M., Campbell, J. R., Chang, V. W. L., Falzon, D., Guglielmetti, L., Isaakidis, P., Kempker, R. R., Kipiani, M., Kuksa, L., Lange, C., Laniado-Laborín, R., Nahid, P., Rodrigues, D., ...., Menzies, D. (2020). Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: An individual patient data meta-analysis. The Lancet Respiratory Medicine, 8(4), 383–394. https://doi.org/10.1016/S2213-2600(20)30047-3
   PubMed Web of Science ®Google Scholar
• Massud, A., Sulaiman, S. A. S., Ahmad, N., Shafqat, M., Ming, L. C., & Khan, A. H. (2022). Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients: Analysis from a prospective study. Frontiers in Pharmacology, 2(13), 883483. https://doi.org/10.3389/fphar.2022.883483. eCollection 2022.
   Google Scholar
• Merid, M. W., Gezie, L. D., Kassa, G. M., Muluneh, A. G., Akalu, T. Y., & Yenit, M. K. (2019). Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study. BMC Infectious Diseases, 19(1), 1–12. https://doi.org/10.1186/s12879-019-3919-1
   PubMedGoogle Scholar
• Nathanson, E., Gupta, R., Huamani, P., Leimane, V., Pasechnikov, A., Tupasi, T., Vink, K., Jaramillo, E., & Espinal, M. A. (2004). Adverse events in the treatment of multidrug-resistant tuberculosis: Results from the DOTS-Plus initiative. The International Journal of Tuberculosis and Lung Disease, 8(11), 1382–1384.
   PubMed Web of Science ®Google Scholar
• Naz, F., Ahmad, N., Wahid, A., Ahmad, I., Khan, A., Abubakar, M., Khan, S. A., Khan, A., Latif, A., & Ghafoor, A. (2021). High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: A multicentre retrospective observational analysis. BMC Infectious Diseases, 21(1), 1–11. https://doi.org/10.1186/s12879-020-05706-z
   PubMed Web of Science ®Google Scholar
• Ngoc, N. B., Vu Dinh, H., Thuy, N. T., Quang, D. V., Huyen, C. T. T., Hoa, N. M., Anh, N. H., Dat, P. T., Hoa, N. B., Tiemersma, E., & Nhung, N. V. (2021). Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam. PLoS One, 16(9), e0255357.
   PubMed Web of Science ®Google Scholar
• Ravichandran, M., Rajaram, M., Munusamy, M., & Munisamy, M. (2022). Pharmacovigilance of antitubercular therapy in tuberculosis. Cureus, 14(2), e21915.
   PubMedGoogle Scholar
• Sagwa, E. L., Mantel-Teeuwisse, A. K., & Ruswa, N. C. (2014). Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: A retrospective cohort study. Journal of Pharmaceutical Policy and Practice, 7(1), 1–8. https://doi.org/10.1186/2052-3211-7-14
   PubMedGoogle Scholar
• Sanchez-Padilla, E., Marquer, C., Kalon, S., Qayyum, S., Hayrapetyan, A., Varaine, F., Bastard, M., & Bonnet, M. (2014). Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: A quantitative and qualitative study. The International Journal of Tuberculosis and Lung Disease, 18(2), 160–167. https://doi.org/10.5588/ijtld.13.0369
   PubMed Web of Science ®Google Scholar
• Seddon, J. A., Godfrey-Faussett, P., Jacobs, K., Ebrahim, A., Hesseling, A. C., & Schaaf, H. S. (2012). Hearing loss in patients on treatment for drug-resistant tuberculosis. European Respiratory Journal, 40(5), 1277–1286. https://doi.org/10.1183/09031936.00044812
   PubMed Web of Science ®Google Scholar
• Selimoglu, E. (2007). Aminoglycoside-induced ototoxicity. Current Pharmaceutical Design, 13(1), 119–126. https://doi.org/10.2174/138161207779313731
   PubMed Web of Science ®Google Scholar
• Shin, S., Furin, J., Alcántara, F., Hyson, A., Joseph, K., Sánchez, E., & Rich, M. (2004). Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest, 125(3), 974–980. https://doi.org/10.1378/chest.125.3.974
   PubMed Web of Science ®Google Scholar
• Shin, S. S., Hyson, A. M., Castaneda, C., Sánchez, E., Alcántara, F., Mitnick, C. D., Fawzi, M. C. S., Bayona, J., Farmer, P. E., Kim, J. Y., & Furin, J. J. (2003). Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease, 7(4), 347–353.
   PubMed Web of Science ®Google Scholar
• Shin, S. S., Pasechnikov, A. D., Gelmanova, I. Y., Peremitin, G. G., Strelis, A. K., Mishustin, S., Barnashov, A., Karpeichik, Y., Andreev, Y. G., Golubchikova, V. T., Tonkel, T. P., Yanova, G. V., Yedilbayev, A., Rich, M. L., Mukherjee, J. S., Furin, J. J., Atwood, S., Farmer, P. E., Keshavjee, S., & Golubchikova, V. (2007). Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. The International Journal of Tuberculosis and Lung Disease, 11(12), 1314–1320.
   PubMed Web of Science ®Google Scholar
• Sturdy, A., Goodman, A., José, R. J., Loyse, A., O'Donoghue, M., Kon, O. M., Dedicoat, M. J., Harrison, T. S., John, L., Lipman, M., & Cooke, G. S. (2011). Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: A study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy, 66(8), 1815–1820. https://doi.org/10.1093/jac/dkr221
   PubMed Web of Science ®Google Scholar
• Törün, T., Güngör, G., Özmen, I., Bölükbaşı, Y., Maden, E., Bıçakçı, B., Ataç, G., Sevim, T., & Tahaoğlu, K. (2005). Side effects associated with the treatment of multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease, 9(12), 1373–1377.
   PubMed Web of Science ®Google Scholar
• Wahid, A., Ahmad, N., Ghafoor, A., Latif, A., Saleem, F., Khan, S., Atif., & Iqbal, Q. (2021). Effectiveness of shorter treatment regimen in multidrug-resistant tuberculosis patients in Pakistan: A multicenter retrospective record review. The American Journal of Tropical Medicine and Hygiene, 104(5), 1784–1791. https://doi.org/10.4269/ajtmh.20-1134
   PubMed Web of Science ®Google Scholar
• Wahid, A., Ghafoor, A., Khan, A., Al-Worafi, Y., Latif, A., Shahwani, N., Atif, M., Saleem, F., & Ahmad, N. (2022). Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country. Frontiers in Pharmacology, 13, 973713. https://doi.org/10.3389/fphar.2022.973713. eCollection 2022.
   PubMed Web of Science ®Google Scholar
• WHO. (2016). WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. October 2016 revision. https://iris.who.int/bitstream/handle/10665/250125/9789241549639-eng.pdf?sequence=1.
   Google Scholar
• WHO. (2020). Global tuberculosis report 2020. World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. https://iris.who.int/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1.
   Google Scholar
• WHO. (2022). WHO consolidated guidelines on tuberculosis. Module 4: Treatment - drug-resistant tuberculosis treatment, 2022 update. World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. https://iris.who.int/bitstream/handle/10665/365308/9789240063129-eng.pdf?sequence=1.
   Google Scholar
• WHO. (2023). Global tuberculosis report 2023. World Health Organization. Licence: CC BY-NC-SA 3.0 IGO. https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequence=1.
   Google Scholar
• Wrohan, I., Redwood, L., Ho, J., Velen, K., & Fox, G. (2021). Ototoxicity among multidrug-resistant TB patients: A systematic review and meta-analysis. The International Journal of Tuberculosis and Lung Disease, 25(1), 23–30. https://doi.org/10.5588/ijtld.20.0217
   PubMed Web of Science ®Google Scholar
• Xing, W., Zhang, R., Jiang, W., Zhang, T., Pender, M., Zhou, J., Pu, J., Liu, S., Wang, G., Chen, Y., Li, J., Hu, D., Tang, S., & Li, Y. (2021). Adherence to multidrug resistant tuberculosis treatment and case management in Chongqing, China–a mixed method research study. Infection and Drug Resistance, 14, 999-1012.
   Web of Science ®Google Scholar
• Zhang, Y., Wu, S., Xia, Y., Wang, N., Zhou, L., Wang, J., Fang, R., Sun, F., Chen, M., & Zhan, S. (2017). Adverse events associated with treatment of multidrug-resistant tuberculosis in China: An ambispective cohort study. Medical Science Monitor, 23, 2348–2356. https://doi.org/10.12659/MSM.904682
   PubMed Web of Science ®Google Scholar